Viramatix is a bio-pharmaceutical company that is dedicated to developing peptide-based therapeutics for viral diseases of unmet medical need. Their lead program focuses on influenza, but they are also working on therapeutics for HIV, RSV, HSV, CMV, and more. Their influenza drugs use a novel mechanism of action that efficiently prevents the development of drug resistant strains.

These compounds have been proven effective against both seasonal and pandemic influenza viruses, as well as non-human influenza viruses. They have undergone extensive testing, including in vitro and in vivo testing, and have shown no significant toxicity or adverse effects. Viramatix has also identified promising leads for CMV, RSV, HSV-2, and HIV, which are currently being tested in animal models for efficacy and in GLP toxicology studies.

With a strong focus on developing safe and effective therapeutics, Viramatix aims to address the unmet medical needs associated with these viral diseases